Abstract
Introduction
Alzheimer's disease (AD) is characterized by a progressive loss of cognitive functions [1, 2] . Formation of neurofibrillary tangles
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(NFTs) and amyloid-b plaques is described as major neuropathological hallmarks of AD, and several transgenic mouse models are designed to produce amyloid-b plaques and/or tau pathologies and to mimic the cognitive deficits of AD for studying AD pathogenesis [3, 4] . Neuroinflammation, especially the activation of microglia is heavily debated to contribute to disease progression and to worsen late-stage pathology [5] [6] [7] . Microglia cells are located directly at sites of amyloid deposits in AD brains, where they are supposed to phagocytose the amyloid plaque material [8, 9] . Several reports suggest that in more advanced stages of plaque pathology and AD, microglia become increasingly dysfunctional in phagocytosis, in cell proliferation, motility, signaling, and in proteostasis, all contributing to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 an altered microglia phenotype [10] . The occurrence of peripheral immune cells in the brain, specifically T-cells, and their functional role and interaction with brain resident glial cells is currently discussed. For example, there is evidence for increased T-cell homing into the aged but otherwise healthy brain [11, 12] . Moreover, higher T-cell numbers are found in the brains of several amyloid plaque mouse models [13] . However, the specific T-cell subtypes, their functional relevance, and a possible modulatory activity of T-cells in brains with plaque pathology are still controversial [14] .
Besides neuroinflammation, altered levels of adult neurogenesis are reported to manifest along AD pathology in several amyloid-b transgenic mouse models [15] . Adult hippocampal neurogenesis is the production of new functional neurons from neural stem and progenitor cells and takes place in specific neurogenic niches in the mammalian brain, namely the subgranular zone of the dentate gyrus and the subventricular zone of the lateral ventricle walls [16] [17] [18] [19] . There, stem cells give rise to neuronal progenitor cells, which mature and integrate functionally in the existing neuronal network [20] . The population of neuronal precursors or young immature neurons can be identified by its expression of the microtubule-associated protein doublecortin (DCX) [21, 22] .
We recently demonstrated changes in hippocampal neurogenesis already at very early stages of disease pathology in transgenic amyloid-b animal models, before the manifestation of amyloid-b plaques [23] . In the frame of this analysis, we made the surprising finding of DCXimmunoreactive cells outside the neurogenic niche at sites of amyloid deposits. Here, we present a detailed analysis of the identity of DCX-immunoreactive cell populations associated with amyloid plaques in cortical and hippocampal brain regions of various transgenic amyloid mouse models and in human brains with plaque pathology and in AD specimen. We report for the very first time on DCXimmunoreactive microglia in amyloid mouse models and on DCX-positive T-cells that presumably infiltrate the brain parenchyma of AD transgenic mice and tightly associated with the resident microglia.
Material and methods

Animals
Female amyloid-b precursor protein (APP) Swedish PS1 dE9 (APP-PS1) mice [24] expressing a chimeric mouse or human mutant amyloid precursor protein (Mo/ HuAPP695swe) and a mutant human presenilin 1 (PS1 dE9) both directed to CNS Q6 neurons under the prion protein promoter (Jackson Laboratory, http://www.jax.org/strain/ 005864) were used. For brain histology, we analyzed mice at 3, 10, and 13 months of age. Age-matched nontransgenics derived from the breeding of APP Swedish PS1 dE9 were used as control animals. Mice were housed at the University Hospital Bonn-Clinical Neuroscience in groups under standard conditions at a temperature of 22 C and a 12 h light or dark cycle with ad libitum access to standard food and water. Animal care and handling were performed according to the Declaration of Helsinki and approved by local ethical committees. Brain sections of the APP-Lon/Swe mice overexpressing hAbPP751 with the London (V717I) and Swedish (K670M/N671L) mutations [25, 26] and the transgenic APP-SDI mouse model overexpressing human amyloid-b precursor protein (APP 770 isoform) with the Swedish K670N/M671L, Dutch E693Q, and Iowa D694 N mutations [27, 28] were kindly provided by Prof. Christian Humpel (Laboratory of Psychiatry and Experimental Alzheimer's Research, Department of Psychiatry Psychotherapy and Psychosomatik, Medical University of Innsbruck, Austria). Brain sections from transgenic Tg2576 mice [29, 30] overexpressing the human APP Swedish mutation and wild type littermates at postnatal ages from 3 to 18 months were kindly provided by Prof. Steffen R€ oßner (Paul Flechsig Institute for Brain Research, University of Leipzig, Germany). Brain sections from DCX knockout mice (DCX-KO) and age-matched controls [31] were kindly provided by Fiona Francis (Institut du Fer a Moulin, Paris, France). Brain sections of 8-month-old human a-synuclein overexpressing mice (D-line), a model of synucleinopathy and of Lewy body dementia [32] [33] [34] , were included in the study.
Behavior test
For analysis of spatial learning and memory function, Morris water maze (MWM) test was performed in accordance with the local Animal Health Commission (BMWFW-66.019/0032-WF/V/3 b/2016). This MWM paradigm was performed as previously published [35] . For behavior analysis, 13-to 15-month-old female and male APP-PS1 and age-matched Nestin-CreERT2/R26R-YFP control animals [35, 36] were used (n 5 4/group). For the MWM test, a 108 cm round basin arena filled with 22 6 1 C warm water was used. A 10 ! 10 cm square platform was placed 1 cm below the water surface in the maze. Big black cue symbols were put on each wall of the basin and the testing room to allow the animals spatial orientation. The experimental setup was not changed throughout the whole learning session and performed under constant light conditions. Water maze trials (maximum 60 s) for learning were performed twice a day for a total of 5 days. On each trial, every mouse was put in the water and given 60 s to swim and locate the submerged platform. If the platform was not detected within 60 s, the animal was guided onto the platform and allowed to remain there for 10 s to learn the spatial position of the platform. Only on the first trial of day 1, the platform was marked with a black flag to visualize the platform location to the mice. On day 6, an additional memory paradigm was performed by removing the platform, and mice were tracked for 60 s. The swim path, that is, the total distance moved and the swim speed was recorded using EthoVision software (XT 9.0.726, Noldus). In the absence of the platform during the last session, the time the animals spent in the platform quadrant and the visits in the platform quadrant were additionally calculated.
Human brain samples
We used 7 mm hippocampal sections from formalinfixed paraffin-embedded brain samples which were obtained from the Newcastle Brain Tissue Resource in accordance with Newcastle University ethics board and ethical approval awarded by the Joint Ethics Committee of Newcastle and North Tyneside Health Authority (reference: 08/H0906/136).
Irrespective of clinical diagnoses, all brains underwent neuropathological examination according to a routine protocol that uses standardized neuropathological scoring or grading systems, including NFT Braak staging [37, 38] , Consortium to Establish a Registry for Alzheimer's Disease scores [39] , Newcastle/McKeith Criteria for Lewy body disease [40] , National Institute on Aging-Alzheimer's Association guidelines [41] , and Thal phases of amyloid-b deposition [42] . Our study group consisted of 14 AD cases which showed NFT Braak stages 4-6 and fulfilled the criteria for high AD neuropathological change according to the National Institute on Aging-Alzheimer's Association guidelines [41] and besides classical AD pathology (i.e., NFTs, amyloid plaques, and neuritic plaques) did not show any other pathology (e.g., Lewy bodies, TDP
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-43 positive intracellular inclusions) in the hippocampus. As controls, we used seven cases with NFT Braak stages 0 to 3, which showed no or only very limited amounts of amyloid pathology in the hippocampus.
Perfusion and tissue processing
APP-PS1 animals were anesthetized and transcardially perfused for immunohistochemistry as previously described [43] . Following perfusion, the brains were extracted and postfixed in 4% paraformaldehyde, sodium phosphate buffer solution (PBS, 0.1 M; pH 5 7.4) over night at 4 C. The brains were cryoprotected and transferred into 30% sucrose in 0.1 M sodium PBS (pH 5 7.4). Sagittal sections of 40 mm were cut on dry ice with a sliding microtome.
Immunohistochemistry
Fluorescence immunohistochemistry of mouse tissue was performed on free-floating sections as previously described [23, 43] . Antigen retrieval was performed depending on the used primary antibody by steaming the sections for 15-20 min in citrate buffer (pH 5 6.0, Sigma). The following primary antibodies were used:
Rabbit anti-DCX (1:300, Cell Signaling), normal rabbit IgG control (prediluted to the concentration of rabbit anti-DCX c 5 156 mg/mL and finally used at 1:300, Cell Signaling), goat anti-Iba1 (1:500, Abcam), rat anti-CD45 (1:100, Millipore), mouse anti-Ab (1:1000, Covance), sheep anti-TREM2 (1:300, R&D Systems), rat anti-CD68 (1:250, Serotec), rat anti-CD3 (1:100, Bio-Rad), rat anti-CD8 (1:100, eBioscience), goat anti-PCNA (1:300, Santa Cruz Biotechnology), mouse anti-Nestin (1:300, Abcam), goat anti-Sox2 (1:1000, Santa Cruz Biotechnology), mouse anti-PSA-NCAM (1:2000, Millipore), chicken anti-GFAP (1:2000, Abcam), goat anti-Olig2 (1:300, R&D Systems), mouse anti-NeuN (1:500, Millipore), rat anti-B220 (1:100, eBioscience), rat anti-Ly6G (1:100, eBioscience), rat anti-CD169 (1:50, Bio-Rad), rat anti-CD4 (1:100, eBioscience), and rat anti-Foxp3 (1:100, eBioscience). For a synuclein staining rat anti-a-synuclein (1:50, Enzo) antibody was used and antibody incubation time was increased for a total of 2 days.
Sections were extensively washed in PBS and incubated for 3 h at RT For qualitative amyloid-b plaque staining, Thioflavin S (1 mg/mL, 1:625, Sigma) was added to the secondary antibody solution. Tissue sections from AD brains were additionally treated with 0.2% Sudan Black (Sigma) in 70% ethanol for 1-2 minutes to reduce the autofluorescence in tissue from old animals [44] . After this treatment, the sections were extensively washed in PBS and mounted onto microscope glass slides (Superfrost Plus, Thermo Scientific). Brain sections were cover slipped semi-dry in ProLong Gold Antifade Mountant (Life Technologies) or Fluorescence Mounting Medium (Dako).
Human samples were immunohistologically stained as follows: after antigen retrieval and H 2 O 2 quench, sections were incubated in a primary antibody for 1 hour at room temperature. The following primary antibody was used: rabbit anti-DCX (1:3000, Abcam). Visualization was performed using the Menarini Diagnostics X-Cell DAB kit (MP-XCPDAB-U100) following the outlined protocol. All washes were done in TBS Q9 buffer pH 7.6.
Microscopy, visualization, and image processing
For qualitative and quantitative microscopic analysis of mouse tissue, confocal laser scanning microscopy was performed using a LSM 700 and LSM 710 from Zeiss. Representative images were taken as z-stack image from the stained sections. Orthogonal projections (maximum intensity) of the images were created and depicted in respective false colors using Zen 2012 blue edition software. For 3D reconstruction, images were processed at the LSM 710 using the Zen 2011 SP7 (black) software. Images were generated using the 3D tool with surface representation function, and each staining was depicted in respective false colors. Representative images of human DCXstained samples were taken using a Nikon Eclipse E600 microscope and the NTS Elements Imaging Software (version 4.30.01).
Western blot analysis
For protein analysis, brains from 13-month-old APP-PS1 and littermates (n 5 4/group) were extracted, and the hippocampus and cortex were dissected from one hemisphere per animal. Cortex and hippocampus regions were immediately frozen on dry ice and stored for further processing at 280 C. Brain regions were homogenized using an electric homogenizer pestle in 500 mL RIPA Q10 buffer (50 mM Tris-HCl pH 7.4, 1% NP-40 [Sigma], 0.25% Na-deoxycholate [Sigma] , and 150 mM NaCl, 1 mM EDTA), and protease (cOmplete, Roche) and phosphatase inhibitors (PhosStop, Roche). Afterward, lysates were manually dissociated using surgical needles of 20G and 27G size (Dispomed) to obtain a homogeneous sample solution. Samples were thoroughly vortexed, placed on an orbital shaker at 4 C for 30-60 min, and were then centrifuged for 20 min at 14,000 g. Supernatants were collected, and protein concentrations were calculated using Pierce BCA Protein Kit (ThermoFisher Scientific) following manufacturer's instruction. Total protein (7.5 mg) was denaturated for 5 min at 98 C in RIPA buffer with SDS Q11 sample loading buffer and loaded onto a Mini-Protean TGX stain-free precast gel (Bio-Rad). After standard SDS-polyacrylamide gel electrophoresis, proteins were blotted onto a Mini-Format 0.2 mm nitrocellulose membrane using the Trans-Blot Turbo System (Bio-Rad) according to manufacturer's instructions. Afterward, the membranes were washed in TBS-T (TBS with 0.1% Tween) for a total of three washes. Membranes were blocked for 1 h at RT with TBS-T containing 4% BSA
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(Sigma) and incubated over night at 4 C with following primary antibodies: rabbit anti-DCX (1:1000, Cell Signaling) and mouse anti-b-actin (1:2000, Sigma). The next day, membranes were washed three times 10 min in TBS-T and incubated with following secondary antibodies for 2 h at RT: donkey anti-rabbit Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 568 (1:1000, all Molecular Probes). After three times 10 min washes of TBS-T, fluorescence signals were detected using the ChemiDoc Mp Imaging System (Bio-Rad).
ImageJ (1.44p) and the function "Analyze Gel" was used for quantitative analysis. The protein band of interest and the loading control were selected from every loaded sample, and the area under the signal peak was calculated. After manual background subtraction, the protein band densities were normalized to b-actin. In addition, the densities of APP-PS1 lysates were normalized to WT Q13 lysates and expressed as relative density to control lysate in %.
Electron microscopy
For ultrastructure analysis, 13-month-old APP-PS1 mice and WT controls were perfused with 4% paraformaldehyde and 0.5% glutaraldehyde in 0.1 M PB. Brains were removed, and 50 mm sagittal sections were cut using a vibratome and stored in 0.1 M PB with 0.05% sodium azide. Sections with brain areas of interest were selected and preembedding 3,3 0 -Diaminobenzidin immunostaining was performed as already described [23] . As primary antibody, the rabbit anti-DCX (1:300, Cell Signaling) antibody was used and incubated over night at RT. After several washes in PBS, sections were incubated for 3 h with goat anti-rabbit biotinylated antibody (1:500, Vector). To increase staining signal, sections were incubated in Vectastain ABC Hrp Kit (Vector) for 1 h according to manufacturer's instructions. After three times 10 min washing in PBS, sections were transferred to 3,3 0 -Diaminobenzidin using the Peroxidase Substrate Kit (Vector) following manufacturer's instructions. Sections were rigorously washed and osmificated by incubating in 1% OsO 4 (EMS Q14 ) in 0.1 M PB for 1 h. Following three washes for 10 min in distilled water, sections were incubated in Uranyl Acetate Replacement Stain-(EMS) for 30 min. Sections were dehydrated by incubation in an increasing series of ethanol and transferred to propylenoxide (EMS) before embedding in araldite durcupan (four component resin, Sigma) over night in aluminum foil cups at RT. On the next day, the slices were gently transferred to acetate slides (100 micron color laser printer film, 5 star office), covered with small amounts of araldite and coated with a second acetate slide and hardened in an oven at 60 C for 3 days. Regions of interest were cut out of the embedded sections, followed by removing one side of the acetate slide and glueing on an araldite durcupan block with cyanoacrylate adhesive (UHU
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). This protocol was performed with small modifications according to the research group of Jos e-Manuel Garcia Verdugo [45, 46] . After removing the acetate slides and careful trimming of the samples into a trapezial shape, semithin sections of 1-1.5 mm were generated using a Reichert Ultracut S ultra-microtome (Leica). Semithin sections were transferred to object slides and were stained with 1% Toluidine blue for orientation. After identification of stained cells, ultrathin sections of 70 nm were directly cut using a diamond knife (Diatome). Sections were stretched with chloroform and subsequently collected with 75 mesh copper grids of 3 mm diameter coated with 0.2% Formvar solution. Grids were dried and analyzed using a Zeiss Leo 910 electron microscope with an integrated Zeiss 906 TRS Q16 USB camera. The utilized software was ImageSP, version 1.2.4.29 from TRS & Sys Prog. 378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444   445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511 
Qualitative and quantitative analysis of immunohistological data
For qualitative image analysis, amyloid plaques in the cortex, corpus callosum, and hippocampus from 10-to 13-month-old APP-PS1 animals were analyzed. Quantitative analysis of mean particle size and percentage area of staining was performed in 13-month-old APP-PS1 and age-matched WT littermates. For each animal, four fields of view in the cortex and hippocampus were photographed as z-stack at 40! magnification using a confocal laser scanning microscope (n 5 3/group). Images were analyzed using ImageJ software (1.44p). For every image, maximum intensity projections were generated, and the threshold for each representative staining was manually set. The number of particles (bigger than 1 mm 2 ) and the particle areas [mm 2 ] were calculated for each staining using the ImageJ tool "Analyse particles". The total tissue area [in mm 2 ] of each image was calculated, and the % area (area of stained particles/field of view) was calculated.
Light microscopic analysis of human brain tissue was done as follows: images were captured at !100 magnification, three from each region of interest: dentate gyrus, entorhinal cortex, and the CA1 and CA2 of the hippocampus, using a Zeiss Axio Scope A1 microscope with an Infinity 2 camera attached and using the Infinity 2-1C imaging software. Image analysis was performed by Image Pro Analyzer, version 6.3 software blind to disease state. The area of interest was identified, and positive staining was highlighted. Measurements for area, per area, and integrated optical density were taken for statistical analysis. All statistical analyses were done using GraphPad Prism.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (GraphPad Software, version 5-7). Outliers were identified by Grubb test analysis (https://graphpad.com/quickcalcs/ Grubbs1.cfm). Values between two groups were compared by the two-tailed unpaired Student's t-test with or without Welch's correction for normally distributed data. Two-way analysis of variance with Bonferroni post hoc test was performed for learning curve analysis of the MWM data. P values of P , .0001 (****) and P , .001 (***) were considered most significant, P , .01 (**) highly significant, and P , .05 (*) significant. Values were expressed as mean 6 standard deviation or mean 6 standard error of the mean.
Results
DCX-immunoreactive cells cluster at amyloid-b plaques in mouse brains and in human AD brain specimen
By analyzing amyloid plaque pathology in the cortex and hippocampus of 3-, 10-, and 13-month-old APP-PS1 animals, we recognized the presence of plaque-associated DCX-immunoreactive cells. These cells appeared with the onset of amyloid-b plaque deposition. Whereas, 3-monthsold APP-PS1 animals were mostly devoid of amyloid-b plaques, 10-and 13-month-old animals already showed severe plaque pathology in hippocampal and cortical brain regions (Fig. 1A and 1B) .
Interestingly, we observed increased DCX immunoreactivity clustered at these amyloid deposits (Fig. 1A and 1B) . Three-month-old APP-PS1 animals did barely show any DCX immunoreactivity outside the neurogenic niches in cortical or hippocampal brain regions; however, increased DCX-positive staining was observed in cells surrounding cortical and hippocampal plaques of 10-and 13-month-old APP-PS1 animals ( Fig. 1A and 1B) . To test the specificity of the DCX antibody, appropriate negative controls were performed: omitting of primary antibody (Fig. 1C) and staining with an isotype control antibody (Fig. 1C  0 ) to detect the level of nonspecific background signal. In addition, we proved the specificity of the DCX antibody used in this study, by staining DCX-KO brain tissue. The KO tissue did not show any staining in the dentate gyrus of the hippocampus (Fig. 1C 00 ) or in any other brain region of DCX-KO animals.
To confirm the DCX protein expression in the APP-PS1 brain, we isolated proteins from the hippocampus and cortex of 13-month-old WT and APP-PS1 animals and performed Western blot analysis. In accordance with the IHC Q17 data, the Western blot analysis showed increased amounts of DCX protein in the cortex of aged APP-PS1 animals compared with WT ( Fig. 1D and 1E ). This difference in DCX protein expression was not detected in hippocampal lysates, most likely due to the fact that the adult hippocampus expresses already high levels of DCX protein and that the further increase due to plaque-associated elevation of DCX expression might not be detected by Western blotting (Fig. 1D and 1E ). Alternatively, a reduced level of hippocampal neurogenesis at this stage might cover the elevation of plaque-associated DCX protein levels.
Next, we investigated whether the appearance of DCX cells clustering around amyloid plaques was specific for the APP-PS1 mouse model or whether this was a more general phenomenon related to amyloid plaque pathologies. In all additional transgenic AD animal models tested at stages with advanced amyloid pathology, that is, the APP-Lon/Swe (11 months old) the APP-SDI (12 months old) and the Tg2576 (18 months old), DCX-immunoreactive cells were present at sites of amyloid deposits (Fig. 1F) . Moreover, the analysis of human AD brain samples revealed increased DCX staining in hippocampus AD samples with plaques compared with control samples without any amyloid plaques (Fig. 1G) . Furthermore, DCX staining was prominent in hippocampal brain structures of control samples, that is, clinically nondemented, with a detectable amount of plaque pathology (Fig. 1G) . Semi-quantitative analysis revealed that the percentage area for DCX staining was significantly 513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578   579  580  581  582  583  584  585  586  587  588  589  590  591 increased in human CA1 hippocampus regions of AD specimen compared with controls (Fig. 1H) .
Two different DCX expressing cell types cluster at amyloid plaques in brains of APP-PS1 mice
We first hypothesized that the plaque-associated DCX cells might be of neurogenic origin. Therefore, we stained for markers of cell proliferation (proliferating cell nuclear antigen), stem and progenitor cells (Nestin, SOX2, PSA-NCAM), oligodendrocytes (Olig2), astrocytes (GFAP), and neurons (NeuN). However, none of these markers (except proliferating cell nuclear antigen) co-localized with the plaque-associated DCX cells (data not shown, see Table 1 ), suggesting that these cells were not of neurogenic origin. Surprisingly, however, the DCX-positive staining at sites of amyloid deposition in APP-PS1 animals highly colocalized with the microglia marker Iba1 (Fig. 2A) . Interestingly, in areas with almost no amyloid deposits, microglia did barely, if at all, express DCX ( Fig. 2A, rectangle) . However, microglia directly located at sites of the amyloid plaques were observed as highly immunoreactive for DCX ( Fig. 2A, arrow) to the extent that all plaque-associated Iba1 cells were DCX positive. We further observed a second population of DCX-immunoreactive cells, which did not express Iba1 and hence represent a non-microglia population ( Fig. 2A, arrowhead) . To investigate whether some of these DCX1 cells could be infiltrating macrophages or other peripheral immune cells, we performed staining with the pan-leukocyte marker CD45. Remarkably, all amyloid plaque-associated DCX1 cells clearly co-localized with CD45 (Fig. 2B, asterisk) . One fraction of these cells colocalized with Iba1 and showed only very faint expression for CD45 (see Fig. 2B, asterisk) , while the other fraction lacked the expression of Iba1 but was highly positive for CD45 (Fig. 2B, arrow) . Vice versa, all plaque-associated CD45-positive cells were DCX positive. These data suggest the presence of two different DCX-expressing cell populations, one with a microglia identity and one with a hematopoietic origin. In the following, we refer to the cells that lack Iba1 but show high expression of CD45 as CD4511/ DCX1 population; the Iba1 positive but CD45 faintly expressing DCX-immunoreactive population is termed Iba11/DCX1.
Next, we performed quantitative analysis of DCX, Iba1, and CD45 expressions in APP-PS1 brain sections. We analyzed the percentage area (area of stained particles or field of view) for each respective staining in cortical and hippocampal brain regions of 13-months-old APP-PS1 animals and compared age-matched WT littermates. We detected a significant increase in the percentage area for Iba1 and DCX staining in the cortex of APP-PS1 animals compared with WT littermates (Fig. 3A and 3C ). DCX immunoreactivity in the cortex co-localized with Iba11/ CD451 microglia (Fig 3A, insert) . Analysis of the hippocampus revealed a significant increase in percentage area of DCX staining ( Fig. 3B and 3D) . Furthermore, strong CD4511 cells, negative for Iba1, were detected in the brain parenchyma as being highly positive for DCX (Fig. 3C,  asterisk) .
To analyze the DCX expression at sites of amyloid deposits in more detail, we analyzed the ultrastructure of cortical and hippocampal brain regions from APP-PS1 animals using immunoelectron microscopy. DCX immunoreactivity was detected at the inner side of the cell membranes in processes of microglia that were located at sites of amyloid plaques (Fig. 2C, red arrow) . A second population of cells with very strong DCX staining, but a different morphology was detected (Fig. 2D) . In this population, DCX staining was localized within the cytoplasm and at the cortical actin-rich cytoskeleton of these small cells with a roundshaped nucleus and pseudopod-like structures (Fig. 2D , red arrow). These cells were identified by their morphology and CD45 expression (Fig. 2B) as leukocytes.
To summarize, we demonstrated an increased expression of DCX in brains of AD mouse models with already advanced plaque pathology and documented the occurrence of DCX-immunoreactive cells at sites of amyloid-b plaques. These cells were identified as Iba11 microglia and CD451 cells with hematopoietic origin. Ultrastructure analysis revealed intracellular DCX expression in microglia located at sites of amyloid deposition and in cells with leukocyte-like morphology.
DCX-immunoreactive cells at sites of amyloidplaques are positive for markers of phagocytosis and contain engulfed plaque material in APP-PS1 mice
Because DCX-immunoreactive cells were observed very close to the amyloid deposits and co-localized with the microglia marker Iba1, we investigated whether DCX might be involved in amyloid plaque clearance. Therefore, we stained for various markers known to be involved in phagocytosis such as the triggering receptor 2 expressed on myeloid cells (TREM2) and the lysosomal marker CD68. Indeed, strong co-localization of DCX with TREM2-positive cells at sites of amyloid-b staining was detected (Fig. 4A) . Also, we observed co-localization of DCX with CD68-positive microglia (Fig. 4B) . In addition to the described co-localization of DCX with this phagocytosisrelated marker, DCX-immunoreactive cells contained Thioflavin S-positive material in their cytoplasm (Fig. 4C) . Moreover, high resolution images revealed that the DCX-positive cell cytoplasm reached toward the amyloid plaque deposits 780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812  813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846 ( Fig. 4D) . These data strongly suggest that plaqueassociated DCX cells participate in phagocytosing plaque material.
Plaque-associated CD4511/ DCX1 immunoreactive cells are CD31/CD81 T-cells
We further tried to identify the CD4511 hematopoietic DCX-immunoreactive cell population in the APP-PS1 mouse brain in more detail by using various markers of the hematopoietic cell lineage (for details see Table 1 ). The CD4511/DCX1 cell population in the brain of APP-PS1 did not co-localize with markers of B-cells, granulocytes, or monocytes (data not shown). However, we found DCXimmunoreactive CD31 T-cells in the brains of APP-PS1 animals (Fig. 5A) . Those T-cells were randomly distributed in the brains, some were associated with vessels, but some were directly located at sites of amyloid deposition. Because regulatory T-cells (Foxp31) and CD41 T-cells were described to enter mouse brains with massive neurodegeneration and brains of AD animal models [13, 47] , we tested for CD4 and Foxp3 expression in the DCX1/CD31 T-cell population. None of these markers were expressed by the CD4511/DCX 1 cell population. However, the majority of DCX-immunoreactive cells were positive for the T-cell marker CD8 (Fig. 5B, insert) . Confocal imaging and 3D surface representation of high magnification images revealed that many of these DCX-immunoreactive CD81 cells were closely attached to DCX1/Iba11 microglia (Fig. 5C) .
In summary, we detected DCX-immunoreactive cells at sites of amyloid-deposition in APP-PS1 animals. We identified two subpopulations of these cells: one population represents an Iba11 microglia population immunoreactive for DCX, expressing markers for phagocytosis and with incorporated amyloid deposits. A further subpopulation of DCX-immunoreactive cells was positive for the T-cell marker CD3 and was characterized as a CD8-positive T-cell population most likely entering the brain and highly interacting with microglia.
Discussion
We employed a broadly used mouse model for AD, the APP-PS1 mouse model, which is well described to develop a variety of human hallmarks for AD pathology. The APP-PS1 mouse model starts to form amyloid-plaque deposits from 3-4 months of age [23, [48] [49] [50] and along disease progression, it develops reactive astrogliosis [51] , microgliosis or microglia activation [52, 53] , synaptic loss [54] , changes in synaptic long-term potentiation [55] , and even modest neuronal loss adjacent to plaques [56] . These changes in brain structure and function lead to a decline in cognitive performance of these mice, tested in several cognitive behavior tasks [55, 57] . Indeed, we confirmed impaired learning and memory function in APP-PS1 mice using MWM test for spatial learning and memory ( Supplementary Fig. 1 ). Animals were trained to find a water-submerged platform over a time period of 5 days, and the total distance the animals traveled to find the platform was analyzed. APP-PS1 animals significantly traveled higher distances to reach the platform compared with age- Transcriptional regulator expressed on regulatory T-cells -Abbreviations: DCX, doublecortin; PCNA, proliferation; TF, transcription factor. NOTE. Detailed IHC characterization was performed using markers for cell proliferation, stem and progenitor cells, astrocytes, oligodendrocytes, neurons, microglia, phagocytosis, and of the hematopoietic cell lineage. DCX-immunoreactive cells at sites of plaques were negative for markers of neural stem-and progenitor cells, astrocytes, oligodendrocytes or mature neurons. Most interestingly, DCX immunoreactivity colocalized with markers for cell proliferation (PCNA), microglia (Iba1), phagocytosis (TREM2, CD68), and with markers for the hematopoietic cell lineage (CD45, CD3, and CD8).
NOTE. Few (1), moderate (11), and high (111).
matched control animals indicating reduced learning function ( Supplementary Fig. 1A and 1B) . Spatial memory analysis after removal of the platform on day 6 revealed decreased memory functions in APP-PS1 animals compared with age-matched controls ( Supplementary Fig. 1C ). Nevertheless, the APP-PS1 mouse has its limitations as a model for AD. Obviously, spatial learning and memory is only one of the plethoras of cognitive dysfunctions AD patients are suffering from, and therefore, data derived from experiments with APP-PS1 animals should not be overinterpreted. Also, APP-PS1 mice do not develop NFTs by hyperphosphorylation of the tau protein, which is observed in the brains of many AD patients [37] . Finally, the APP-PS1 model represents one of the genetic and familial forms of AD and not the much more frequent sporadic forms. Here, we identify and characterize DCX-immunoreactive cells outside the neurogenic niches at sites of amyloid deposition in the brains of transgenic amyloid-plaque mouse models and in human AD specimen. The plaqueassociated DCX cells were of nonneurogenic origin, as they lacked the expression of stem or progenitor cell markers and those of neuronal and glial cells (see Table 1 ). This print & web 4C=FPO Fig. 2 . DCX in microglia and hematopoietic cells at sites of cortical and hippocampal amyloid plaques in APP-PS1 mice: DCX immunoreactivity strongly colocalized with the microglia marker Iba1 (A). Microglia close to the amyloid plaques showed DCX expression (arrow), whereas microglia in areas with no amyloid deposition were barely positive for DCX (rectangle in A). Furthermore, a subpopulation of DCX-immunoreactive cells lacking the expression of Iba1 was detected (A, triangle). Using the pan-leukocyte marker CD45 for further characterization of the DCX-immunoreactive population revealed two distinct DCX cell types at sites of amyloid deposition: a DCX1/Iba11/CD451 microglia (asterisk) and a DCX1/Iba12/CD4511 population (B, arrow). (C) Ultrastructure analysis of DCX-DAB immunostained APP-PS1 brains showed intracellular DCX protein localization in microglia (m) and leukocytelike cells (leu) at sites of neuritic cortical and hippocampal amyloid plaques (P). Microglia at sites of an amyloid core and dystrophic neurites (dN), containing electrodense laminar bodies, showed intracellular DCX expression in their processes and in the cytoplasm along their inner cell membrane (C, red arrows). In addition, strong polarized DCX expression lining the inner cell membrane was observed in leukocyte-like cells of round shape, with pseudopod-like processes (D, red arrows). In A, B DAPI was used as nucleus stain. Scale: 50 mm (A, B), 1 mm (C, D) and 500 nm (C, D inserts). Cell 1116  1117  1118  1119  1120  1121  1122  1123  1124  1125  1126  1127  1128  1129  1130  1131  1132  1133  1134  1135  1136  1137  1138  1139  1140  1141  1142  1143  1144  1145  1146  1147  1148  1149  1150  1151  1152  1153  1154  1155  1156  1157  1158  1159  1160  1161  1162  1163  1164  1165  1166  1167  1168  1169  1170  1171  1172  1173  1174  1175  1176  1177 1183  1184  1185  1186  1187  1188  1189  1190  1191  1192  1193  1194  1195  1196  1197  1198  1199  1200  1201  1202  1203  1204  1205  1206  1207  1208  1209  1210  1211  1212  1213  1214  1215  1216  1217  1218  1219  1220  1221  1222  1223  1224  1225  1226  1227  1228  1229  1230  1231  1232  1233  1234  1235  1236  1237  1238  1239  1240  1241  1242  1243  1244  1245  1246  1247  1248   1249  1250  1251  1252  1253  1254  1255  1256  1257  1258  1259  1260  1261  1262  1263  1264  1265  1266  1267  1268  1269  1270  1271  1272  1273  1274  1275  1276  1277  1278  1279  1280  1281  1282  1283  1284  1285  1286  1287  1288  1289  1290  1291  1292  1293  1294  1295  1296  1297  1298  1299  1300  1301  1302  1303  1304  1305  1306  1307  1308  1309  1310  1311  1312  1313  1314 is essential knowledge, as DCX is generally used as a marker for young immature neurons and for neurogenesis [21, 22] . Thus, elevated DCX expression in brains with neurodegeneration outside of the neurogenic niches could easily be misinterpreted as enhanced neurogenesis. There were no obvious signs of potential migration of these cells from the neurogenic niches, instead they were highly proliferative (data not shown) and clustered at plaques in the transgenic animal models. This may lead to the assumption that at least some of these cells were generated locally. The plaque-associated DCX1 cells were identified as immune cells, more specifically as Iba11 microglia and as CD81 T-cells. These two cell types appeared in close proximity to each other, suggesting that they might interact and modulate phagocytic and/or immune activities.
DCX is highly expressed in the developing brain, specifically in migrating or differentiating neurons [58, 59] . In the adult organism, its expression is mainly confined to neuronal precursor cells and young immature neurons in the neurogenic niches of the dentate gyrus and of the subventricular zone of the lateral ventricle [21, 22] . There is very little evidence for DCX expression in the adult uninjured brain in cells outside the neurogenic regions, and if it appears then, that DCX expression in such areas is confined to cells of neurogenic origin. For example, in the piriform cortex, a pool of neurons with an immature phenotype retains DCX expression in the adult [60] , and it is thought that such immature DCX neurons might provide the brain circuitry with increased plasticity [61, 62] . Interestingly, cortical DCX expression in nonneurogenic regions is unaffected by age or by neurogenesis-inhibiting interventions such as radiation [63] .
In animal models of stroke, leptomeningeal cells express DCX, and these cells might contribute to repair processes [64] . Also, after stroke, the production of DCX cells in the subventricular zone is increased, and DCX-positive cells migrate toward the lesion site [65] . Besides immature neurons, GFAP-positive astroglia have been shown to express DCX after an ischemic lesion [66] . Furthermore, DCX expression was described in oligodendrocyte precursor cells of healthy rodent brains [67] . Taking into account that levels of adult neurogenesis, that is, levels of DCX 1 neuronal progenitors, correlate with cognitive behavior in rodent animal models [68] , the nonneurogenic DCX protein expression detected along amyloid pathology has to be carefully interpreted. At least, up to now, there is no correlation between nonneurogenic DCX cells in the brain cognitive outcomes. Nevertheless, one possible interpretation of this might be a beneficial process allowing cellular plasticity and involvement in regeneration rather than being detrimental. To address the question whether nonneurogenic DCX-positive cells are generally present in rodent models for neurodegenerative diseases, we additionally analyzed DCX expression in a Lewy body dementia mouse model with severe a-synucleinopathy in the brain [34] . We did not observe DCX expression in these transgenic mice other than in the hippocampal neurogenic niche, and there was no co-localization with microglia marker (Supplementary Fig. 2 ). Therefore, it is more likely that the herein described nonneurogenic DCX expression is specific for amyloid pathology; however, this would need further investigations. Nevertheless, if so, this harbors the possibility of the future use of DCX to stratify AD brains in neuropathology.
The microglia fraction of the plaque-associated DCX cells co-expressed the microglia markers Iba1, CD68, and TREM2, suggesting that these cells are phagocytic cells. Indeed, they showed incorporated amyloid deposits in their cell soma. Interestingly, non-plaque-associated microglia in the AD brain as well as microglia in wild type mice did barely show any DCX immunoreactivity. This might be an explanation for the fact that DCX was so far never described in microglia of the adult brain. Nevertheless, there is evidence that microglia do express DCX under certain circumstances. A RNA sequence database on embryonic and adult-isolated microglia [69] reveals that microglia during development do express DCX mRNA at considerable amounts compared with all genes (FPKM Q18 46), but they lose DCX expression during postnatal stages (http://web.stanford.edu/group/barres_lab/cgi-bin/geneSear chMariko.py?geneNameIn5DCX).
Also, a transcriptome analysis of amoeboid microglia versus ramified microglia isolated from the corpus callosum of rat brains revealed expression of DCX in microglia. The DCX gene was within the top 25 highly expressed genes in amoeboid microglia but was not expressed in ramified microglia. At the protein level, the authors demonstrated that amoeboid microglia showed positive immunoreactivity for DCX [70] . The function of DCX in developmental or amoeboid microglia is unclear, but as DCX is a microtubule-associated protein involved in neuronal migration [71, 72] , it might as well modulate migration and motility of microglia. Alternatively, DCX might be involved in intracellular processes such as phagocytosis. Phagocytosis is a key function of microglia and involves high motility and plasticity of the intracellular cytoskeleton coordinated by various receptor complexes on the microglia cell surface [9] . DCX might play an essential role in cytoskeletal reorganization specifically in microglia associated with the amyloid-b plaques. Regardless of a putative function of DCX in this process, the morphology and location, as well as the expression of the phagocytosis markers revealed a significantly increased percentage area of DCX staining in APP-PS1 animals compared with WT (D). Furthermore, strongly CD4511 cells negative for Iba1 were detected in the brain parenchyma being highly positive for DCX (asterisk in B). DAPI was used as nucleus stain. Unpaired Student's t-test (mean 6 SD) with or without Welch's correction (n 5 3/group) for each staining was performed (C, D). Scale: 50 mm (A, B) . Abbreviations: DCX, doublecortin; APP-PS1, APP Swedish PS1 dE9; SD, standard deviation. 1316  1317  1318  1319  1320  1321  1322  1323  1324  1325  1326  1327  1328  1329  1330  1331  1332  1333  1334  1335  1336  1337  1338  1339  1340  1341  1342  1343  1344  1345  1346  1347  1348  1349  1350  1351  1352  1353  1354  1355  1356  1357  1358  1359  1360  1361  1362  1363  1364  1365  1366  1367  1368  1369  1370  1371  1372  1373  1374  1375  1376  1377  1378  1379  1380  1381  1382 TREM2 and CD68, and the presence of amyloid plaque material in the DCX cells strongly suggests that they have phagocytic activity and that they contribute to amyloid plaque clearance. The role of TREM2 and of microglia-mediated phagocytosis in AD pathogenesis is evident, as human genetic studies showed a higher risk to develop AD with certain TREM2 variants [73] . Besides TREM2, the co-localization of the DCX cells with CD68 also points toward a critical role in phagocytosis, as CD68 is expressed in lysosomal vesicles [74, 75] . The DCX immunoreactivity was not limited to the microglia cell population at sites of amyloid plaques. We identified a specific hematopoietic T-cell population present in the brain of APP-PS1 animals, which was positive for DCX. Assuming that these cells infiltrated the brain from the periphery, we also analyzed peripheral immune organs, for example, spleen and bone marrow from adult mice, and surprisingly found high DCX immunoreactivity in T-cell-rich areas of this tissue (Supplementary Fig. 3 ). We used various markers of the hematopoietic cell lineage to characterize these cells in the brain of APP-PS1 animals and detected mainly CD81 DCX-immunoreactive T-cells that were in direct contact with microglia. The existence of two subpopulations of nonneurogenic DCX1 cells is fascinating and might be explained by their cellular function: microglia as already discussed previously have to be highly motile for phagocytosis, and T-cells have to form and change their cytoskeleton depending on their activity status [76, 77] . Both functions involve cytoskeleton reorganization and might therefore involve the DCX protein.
The occurrence of peripheral immune cells, specifically T-cells, in the brain and their functional role and interaction with brain resident glial cells is currently discussed, and increased T-cell homing into the healthy aged brain has been reported [11, 12] . Although the increased occurrence of T-cells in the brains of patients with autoimmune diseases such as multiple sclerosis is well documented, the evidence of T-cells in chronic neurodegenerative disease such as AD is less [78] . The occurrence of T-cells in the brain 1450  1451  1452  1453  1454  1455  1456  1457  1458  1459  1460  1461  1462  1463  1464  1465  1466  1467  1468  1469  1470  1471  1472  1473  1474  1475  1476  1477  1478  1479  1480  1481  1482  1483  1484  1485  1486  1487  1488  1489  1490  1491  1492  1493  1494  1495  1496  1497  1498  1499  1500  1501  1502  1503  1504  1505  1506  1507  1508  1509  1510  1511  1512  1513  1514  1515  1516 was first reported in human AD postmortem brain biopsies in 1988 [79] . Elevated numbers of T-cells in the brains of amyloid plaque mouse models has further been documented in several transgenic AD mouse models [13] . This, of course, raises the question whether T-cells might have a modulatory activity, ameliorating or worsening AD pathology [14] . Whereas, studies on regulatory T-cells (Tregs) report on a beneficial function of T-cells by slowing down disease progression and modulating microglia responses to amyloid-b deposits [80] , others report about detrimental effects of Tregs in AD. For example, while in one study, depletion or inhibition of Tregs reversed the cognitive deficits in an AD animal model [47] , the genetic ablation of T-, B-, and natural killer cells in a 5XFAD AD mouse model (Rag-5xfAD) revealed a twofold increase in amyloid-b plaque pathology and exacerbated neuroinflammation. Conversely, bone marrow transplantation in these mice again reduced AD pathology [81] .
We summarized our findings in a hypothesis model for T-cell microglia interaction in amyloid plaque-diseased brains (Fig. 6 ). It will be essential to uncover the functional role of the different T-cell subpopulations in the brain along AD pathology. In particular, research on these cells and their interactions with CNS resident cells such as microglia, neurons, and others might identify new therapeutic targets in future. So far, the functional characterization of these cells is very limited, and their interactions with the brains resident glial cells are not fully understood. We confirmed our main findings in several other amyloid plaque models and even in human AD brains or brains with plaque pathology, considering our finding relevant for the broad AD field. ce 1652  1653  1654  1655  1656  1657  1658  1659  1660  1661  1662  1663  1664  1665  1666  1667  1668  1669  1670  1671  1672  1673  1674  1675  1676  1677  1678  1679  1680  1681  1682  1683  1684  1685  1686  1687  1688  1689  1690  1691  1692  1693  1694  1695  1696  1697  1698  1699  1700  1701  1702  1703  1704  1705  1706  1707  1708  1709  1710  1711  1712  1713  1714  1715  1716 
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Supplementary Q19 Q20 data related to this article can be found at https://doi.org/10.1016/j.jalz.2018.02.017.
RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the literature using traditional (e.g., PubMed) sources and meeting abstracts and presentations. Doublecortin positive cells have been analyzed in AD and in amyloid plaque models of AD, however, always in the context of neurogenic niches. These relevant citations are appropriately cited.
2. Interpretation: Our findings led to an integrated hypothesis describing two populations of doublecortin expressing cells associated with plaques, that is, microglia and CD8 T-cells.
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